Changes in Hong Kong stocks | Kingsley Biotech (01548) rose more than 5%. Institutions are optimistic that AIDD will drive strong growth in the company's life sciences business

The Zhitong Finance App learned that Kingsley Biotech (01548) rose by more than 5%. As of press release, it had risen 5.13% to HK$31.94, with a turnover of HK$493 million.

According to the news, Huatai Securities released a research report saying that Kingsley Biotech recently held the 2026 Investor Day to share industry opportunities, technology platform construction, business layout and long-term growth strategies brought by AIDD. The bank is optimistic about the strong growth of the Chinese AI-Driven Drug Discovery (AIDD) -driven company's life science business, while other businesses are developing in an orderly manner. The bank raised the company's profit forecast for each year from 2026 to 28 to 24 million, 394 million and 586 million US dollars, corresponding to earnings of 1 US cent, 19 US cents and 28 US cents per share; of these, the loss was turned into profit in 2026, and the year-on-year growth rates from 2027 to 2028 were 1,565% and 49%, respectively.

The report points out that as AI accelerates molecular design and candidate generation, experimental verification and data generation are becoming bottlenecks and an important part of value release, and Kingsley is benefiting from AIDD wet test outsourcing requirements. The company expects a compound annual growth rate of 50% to 80% of the total potential market in the life sciences AIDD service market in the next three years; AIDD will drive demand for wet testing from four aspects: more customers, faster iteration cycles, higher verification throughput, and deeper wet testing requirements.